secwatch.observer — SEC 8-K summary
======================================

Issuer:     RespireRx Pharmaceuticals Inc. (—)
CIK:        0000849636
Form:       8-K
Filed at:   2023-04-13T23:59:59+00:00
Accession:  0001493152-23-012080
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 3.02, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RespireRx issues Series J preferred to settle $570K of officer/vendor liabilities
--------------------------------------------------------------------------------

- Exchanged $570K of accrued compensation/debt for 5,700 shares of Series J 8% voting preferred stock.
- Margolis (CFO) and Lippa (Interim CEO) each received 2,100 shares; vendor Radin received 1,500 shares.
- Series J shares have $100 stated value, 8% annual dividend payable in stock, and 100x voting rights.
- Redemption triggers include upfront payments, milestones, or royalties ≥$20M; liquidation preference before common.
- Shares transferred immediately to trusts/affiliates; unregistered offering under Section 4(a)(2).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/849636/000149315223012080/0001493152-23-012080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/849636/000149315223012080/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-012080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer